Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours Β· Estimated delivery Aug 8 - Aug 13
2.4 mg is the only dose taken into phase 3: 11.5% body weight over 68 weeks
Adjust volume per your research protocol
* * 1 The dedicated phase 3 RENEW programme will investigate the efficacy and safety of cagrilintide in people with obesity or overweight and is due to start in Q4 2025
PMC 4145307
Practical considerations for safety and consistency: Use a new sterile insulin syringe for every injection Rotate injection locations to reduce local irritation Inject slowly and wait briefly before removing needle Track daily dosing and site rotation for consistency Human clinical evidence remains limited
Rennekamp, A
US$ 27.45
US$ 21.92
US$ 29.55
US$ 26.35
US$ 20.99
US$ 24.74
US$ 27.73
